Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals annonce le remboursement public de lIMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
Rhythm Pharmaceuticals annonce le remboursement public de lIMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
Curaleaf Reports Third Quarter 2025 Results: Solid Growth and Robust Cash Generation
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
HealthEquity Announces Third Quarter Earnings Date
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
Virgin River Season 7: Everything We Know So Far (November 2025 Update)
What Is 2K Resolution: Understanding Display Standards in 2026